Boston-based pharmaceutical company raises $300M to develop cardiovascular treatments
Cardurion Pharmaceuticals, a Boston-based healthcare technology founded by physician-scientists, has received an investment of up to $300 million from Bain Capital Life Sciences (BCLS) and Bain Capital Private Equity.
The funding is expected to go toward pushing forward with the development of new cardiovascular therapies, bring in additional employees and expand the company as necessary. Cardurion is currently working on a PDE9 inhibitor for treating heart failure and a CaMKII inhibitor designed to treat several cardiovascular conditions.
“We could not be more excited to welcome Bain Capital as investors in this transformational milestone for Cardurion,” Peter Lawrence, Cardurion CEO, said in a statement. “We have a shared vision to continue to build a world-class cardiovascular company pursuing treatments for a broad range of debilitating diseases.”
“This investment will accelerate our progress as we work to create transformative new medicines that deliver value for patients and other key stakeholders,” added Michael E. Mendelsohn, MD, Cardurion founder and chairman. “Cardurion is dedicated to advancing novel mechanisms that yield new treatments for cardiovascular disease, which remains the greatest cause of morbidity and mortality in our society.”
Adam Koppel, MD, PhD, a managing director at BCLS, and Nicholas Downing, MD, a principal at BCLS, will both join Cardurion’s board of directors as a result of this investment.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.